Symbiotec Pharmalab IPO: Price Band, Valuation and Key Risks
Last updated: 13 October 2026
Quick answer: Symbiotec Pharmalab's ₹1,757-crore IPO, about 92% of it an offer for sale, was subscribed around 75 times but listed flat on 1 September 2026: ₹988 on NSE, equal to the issue price, and ₹978.20 on BSE, about 1% lower, per 5paisa. It was priced at roughly 55–58x FY26 earnings. Factual summary, not a recommendation.
Last updated: 13 October 2026 Quick answer: Symbiotec Pharmalab's ₹1,757-crore IPO, about 92% of it an offer for sale, was subscribed around 75 times but listed flat on 1 September 2026: ₹988 on NSE, equal to the issue price, and ₹978.20 on BSE, about 1% lower, per 5paisa. It was priced at roughly 55–58x FY26 earnings. Factual summary, not a recommendation. Key takeaways Listing outcome: listed flat at ₹988 on NSE and about 1% lower at ₹978.20 on BSE on 1 September 2026. Demand: about 75x subscribed overall, up from roughly 1.85x at the end of Day 2. OFS-heavy issue: only ₹150 crore of the ₹1,757 crore was fresh capital; ₹1,607 crore went to selling shareholders. Valuation: roughly 55–58x FY26 earnings (PAT ₹109.90 crore) against an FY26 ROE of about 11.2%. Third-party views only: "Subscribe" calls cited were from SBI Securities, Geojit and Swastika — not Money n Wealth, which makes no recommendation. Update (October 2026): This IPO has closed and listed. Despite being subscribed about 75 times, the issue listed flat on NSE at ₹988 (the issue price) and about 1% lower on BSE at ₹978.20 on 1 September 2026 — heavy subscription did not translate into a listing gain here. The review below was written while the issue was open. Source: 5paisa (https://www.5paisa.com/blog/symbiotec-pharmalab-ipo-listing) . Symbiotec Pharmalab, a global leader in corticosteroid and steroidal hormone APIs, is running a ₹1,757-crore IPO that closes tomorrow, 27 August 2026 — but nearly 92% of that money goes to selling shareholders, not the company itself. Key facts Detail Particulars Bidding dates 24–27 August 2026 (closes tomorrow) Price band ₹938–₹988 per share Lot size 15 shares (₹14,820 at upper band) Issue size ₹1,757 cr — fresh issue only ₹150 cr; OFS ₹1,607 cr Listing BSE & NSE, tentatively 1 September 2026 Lead managers JM Financial, Avendus Capital, Motilal Oswal, Nomura Update: Listing Outcome (October 2026) The Symbiotec Pharmalab IPO has since closed and listed. The figures below are as reported by 5paisa (https://www.5paisa.com/blog/symbiotec-pharmalab-ipo-listing) on listing day; they record what happened and are not a view on the stock. Item Outcome Listing date 1 September 2026 (BSE & NSE) Issue price ₹988 (upper end of the ₹938–988 band) NSE listing price ₹988 — flat to the issue price BSE listing price ₹978.20 — about 1% below the issue price Overall subscription About 75x Listing prices are opening prices on listing day, and the share price has moved since. Check current NSE or BSE data before drawing any conclusion; a listing gain or loss says nothing about future returns. Symbiotec Pharmalab IPO at a glance: ₹938–988 price band, ₹1,757 crore issue with ₹1,607 crore OFS, 75x subscription, flat ₹988 NSE listing and 55–58x P/E Symbiotec Pharmalab IPO: issue facts and listing outcome (September 2026) The business Founded over 30 years ago, Symbiotec makes 60+ corticosteroid and steroidal hormone active pharmaceutical ingredients (APIs), and was the global volume leader in both categories in FY25 (roughly 38% and 24% share respectively). It has cut China-sourced inputs from about 53% to 24% of expenses in two years through backward integration, and is now expanding into higher-margin injectables and fermentation-based biologics. Financial snapshot FY Revenue PAT FY24 ₹723.33 cr ₹100.06 cr FY25 ₹755.98 cr ₹96.79 cr FY26 ₹872.26 cr ₹109.90 cr FY26 ROE is a modest ~11.2% and ROCE ~11.6% — yet the issue prices the business at roughly 55–58 times FY26 earnings, a rich multiple against that return profile. Risks you should know before applying Almost the entire issue is an OFS: of the ₹1,757 cr raised, only ₹150 cr is fresh capital for the company — the rest goes to the promoter entity and two existing investors, Rosewood Investments and India Business Excellence Fund III, cashing out. Rich valuation against modest returns: roughly 55–58x earnings is a premium multiple for an ~11% ROE business, and profit growth (5–8% CAGR) has lagged revenue growth. New capacity is currently loss-making: the injectables and fermentation-based biologics plants posted a combined loss of about ₹28.5 crore in FY26, with roughly ₹970 crore of capital still awaiting regulatory approvals before it can contribute. Litigation: disclosed disputes (tax, criminal and civil) with an aggregate claimed value of about ₹150.79 crore, plus smaller matters involving non-promoter directors and subsidiary Knovea Pharmaceutical. The core steroid-API market itself is small (~₹6,350 cr globally) and growing slowly (1–3% a year to 2030). Strengths Global volume leadership in a hard-to-replicate niche (some products require up to 400 validation steps), 10+ year customer relationships, and a genuine, measurable reduction in China dependence. Several brokerages — including SBI Securities, Geojit and Swastika — have "Subscribe" calls, mostly framed for long-term investors rather than listing-gain seekers. These are the brokerages' own views, not Money n Wealth recommendations. Subscription status and GMP Demand has been building through the week: Day 1 closed at just 0.78 times overall, rising to about 1.85 times by the end of Day 2, with one day of bidding left. Grey market premium has been volatile — from around ₹260 in the days before opening to a peak near ₹403–409, easing back to roughly ₹320–340 more recently. Different trackers show different numbers even on the same day — treat GMP as informal sentiment, not a price forecast. Related reading on Money n Wealth Skyways Air Services IPO: disclosed risks and listing outcome (/insights/skyways-air-services-ipo-review) Lumino Industries IPO: issue facts and listing outcome (/insights/lumino-industries-ipo-review) All IPO and OFS articles on Money n Wealth (/insights/category/ipo-ofs) Direct equity investing with Money n Wealth (/products/equity) FAQs Why does it matter that most of the issue is an OFS? An OFS-heavy structure means the IPO mainly transfers ownership from existing investors to new public shareholders — it doesn't inject much fresh growth capital into the business, which is worth weighing against the pitch. Is a 55–58x P/E justified here? That's a judgment call based on how much you value the company's market leadership and new-segment optionality versus its current ~11% return ratios — there's no universal right answer, but it's a materially richer multiple than the company's own recent earnings growth would suggest on its own. What was the Symbiotec Pharmalab IPO listing price? Symbiotec Pharmalab listed on 1 September 2026 at ₹988 on NSE, the same as its issue price, and at ₹978.20 on BSE, about 1% lower, as reported by 5paisa. These were opening prices; the share price has moved since, so check current NSE or BSE data for the latest price. How many times was the Symbiotec Pharmalab IPO subscribed? The issue was subscribed about 75 times overall by the close on 27 August 2026, according to 5paisa, after being only about 1.85 times subscribed at the end of Day 2. Category-wise final figures are published on the NSE and BSE websites. High subscription did not lead to a listing gain in this case. Does Money n Wealth recommend applying for or buying Symbiotec Pharmalab shares? No. Money n Wealth (Predics Fintech Services Pvt Ltd) is an AMFI-registered mutual fund distributor and APMI-registered PMS distributor, not a SEBI-registered research analyst or investment adviser. This page summarises public information about the Symbiotec Pharmalab issue and its listing; it is not a recommendation to subscribe, buy, hold or sell. The "Subscribe" calls mentioned above belong to the named brokerages. Read the offer document and current exchange data before deciding. More from this week's IPO calendar: Skyways Air Services (/insights/skyways-air-services-ipo-review) , Hy-Tech Engineers (/insights/hy-tech-engineers-ipo-review) , Lumino Industries (/insights/lumino-industries-ipo-review) , ESDS Software Solution (/insights/esds-software-solution-ipo-review) , and today's Hindustan Copper OFS (/insights/hindustan-copper-ofs-2026-how-to-apply) . For a broader look at how such names compare with diversified options, see our mutual fund planning guide (/insights/mutual-fund-planning-guide-india) . Disclaimer: Informational only, not investment advice or a recommendation to apply. IPO investments carry allotment, listing-price and business risk — read the RHP and all disclosures carefully. Money n Wealth does not guarantee allotment, listing gains or returns. Investments are subject to market risks. Money n Wealth (Predics Fintech Services Pvt Ltd) is an AMFI-registered Mutual Fund Distributor (ARN-121995) and APMI-registered PMS Distributor (APRN07444); it is not a SEBI-registered investment adviser and may earn distribution commission on investments made through it.
